Publication: Removing the blindfold on medicines pricing
Open/View Files
Date
2018
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Moon, Suerie. 2018. “Removing the Blindfold on Medicines Pricing.” BMJ (February 26): k840. doi:10.1136/bmj.k840.
Research Data
Abstract
Tisagenlecleucel (Kymriah), one of several promising chimeric antigen receptor T cell (CAR-T) therapies, is the first gene therapy to get US approval. Novartis announced in September 2017 that the leukaemia treatment would cost $475 000 (£340 000; €390 000)—double the median house price in the US, or 60 years of mortgage payments for the average family.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service